Amy N. Schilling

1.1k total citations
19 papers, 913 citations indexed

About

Amy N. Schilling is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Amy N. Schilling has authored 19 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Medicine, 12 papers in Pharmacology and 7 papers in Epidemiology. Recurrent topics in Amy N. Schilling's work include Antibiotic Resistance in Bacteria (13 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Pneumonia and Respiratory Infections (5 papers). Amy N. Schilling is often cited by papers focused on Antibiotic Resistance in Bacteria (13 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Pneumonia and Respiratory Infections (5 papers). Amy N. Schilling collaborates with scholars based in United States, Canada and Singapore. Amy N. Schilling's co-authors include Vincent H. Tam, Elizabeth A. Coyle, Michael Nikolaou, Keith Poole, David Melnick, Russell E. Lewis, Shádi Neshat, Andrea Lay‐Hoon Kwa, Nathan P. Wiederhold and Rebecca Corey and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Critical Care Medicine and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Amy N. Schilling

18 papers receiving 886 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy N. Schilling United States 14 514 489 261 189 141 19 913
Nicolas Grégoire France 24 808 1.6× 875 1.8× 551 2.1× 133 0.7× 160 1.1× 73 1.7k
Sofia K. Kasiakou Greece 14 645 1.3× 888 1.8× 560 2.1× 225 1.2× 158 1.1× 16 1.4k
Michael A. Zhanel Canada 9 389 0.8× 610 1.2× 275 1.1× 183 1.0× 146 1.0× 10 877
Lisa Liolios Australia 8 267 0.5× 627 1.3× 334 1.3× 105 0.6× 164 1.2× 12 930
Neang S. Ly United States 15 538 1.0× 753 1.5× 273 1.0× 129 0.7× 203 1.4× 24 1.0k
Sachin Bhagwat India 19 530 1.0× 638 1.3× 220 0.8× 190 1.0× 227 1.6× 47 1.0k
Roberto Andini Italy 14 289 0.6× 423 0.9× 300 1.1× 160 0.8× 77 0.5× 31 850
Courtney K. Lawrence Canada 7 367 0.7× 573 1.2× 204 0.8× 179 0.9× 152 1.1× 11 803
Kamilia Abdelraouf United States 21 624 1.2× 861 1.8× 305 1.2× 235 1.2× 315 2.2× 57 1.4k

Countries citing papers authored by Amy N. Schilling

Since Specialization
Citations

This map shows the geographic impact of Amy N. Schilling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy N. Schilling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy N. Schilling more than expected).

Fields of papers citing papers by Amy N. Schilling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy N. Schilling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy N. Schilling. The network helps show where Amy N. Schilling may publish in the future.

Co-authorship network of co-authors of Amy N. Schilling

This figure shows the co-authorship network connecting the top 25 collaborators of Amy N. Schilling. A scholar is included among the top collaborators of Amy N. Schilling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy N. Schilling. Amy N. Schilling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Schilling, Amy N., et al.. (2020). 662: Polymyxin B-Induced Cardiopulmonary Arrest. Critical Care Medicine. 49(1). 326–326.
2.
Perez, Katherine K., et al.. (2014). Significant publications on infectious diseases pharmacotherapy in 2013. American Journal of Health-System Pharmacy. 71(22). 1974–1988. 10 indexed citations
3.
Jacobs, David M., Kristi Kuper, William L. Musick, et al.. (2013). Significant publications on infectious diseases pharmacotherapy in 2012. American Journal of Health-System Pharmacy. 70(21). 1930–1940. 12 indexed citations
4.
Tran, Truc T., Nicholas D. Beyda, Jessica Cottreau, et al.. (2012). Significant publications on infectious diseases pharmacotherapy in 2011. American Journal of Health-System Pharmacy. 69(19). 1671–1681. 11 indexed citations
5.
Schilling, Amy N., Elizabeth Neuner, & Susan J. Rehm. (2011). Vancomycin: A 50-something-yearold antibiotic we still don’t understand. Cleveland Clinic Journal of Medicine. 78(7). 465–471. 31 indexed citations
6.
Schilling, Amy N., Rebecca Corey, Mandy C. Leonard, & Bijan Eghtesad. (2010). Acetaminophen: Old drug, new warnings. Cleveland Clinic Journal of Medicine. 77(1). 19–27. 89 indexed citations
7.
Tam, Vincent H., Kimberly R. Ledesma, Amy N. Schilling, et al.. (2009). In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagnostic Microbiology and Infectious Disease. 64(4). 427–433. 16 indexed citations
8.
Tam, Vincent H., et al.. (2009). Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagnostic Microbiology and Infectious Disease. 63(3). 279–285. 15 indexed citations
9.
Nikolaou, Michael, et al.. (2007). Modeling of Microbial Population Responses to Time-Periodic Concentrations of Antimicrobial Agents. Annals of Biomedical Engineering. 35(8). 1458–1470. 19 indexed citations
10.
Tam, Vincent H., Amy N. Schilling, Keith Poole, & Michael Nikolaou. (2007). Mathematical modelling response of Pseudomonas aeruginosa to meropenem. Journal of Antimicrobial Chemotherapy. 60(6). 1302–1309. 25 indexed citations
11.
Tam, Vincent H., Amy N. Schilling, Mark LaRocco, et al.. (2007). Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clinical Microbiology and Infection. 13(4). 413–418. 47 indexed citations
12.
Tam, Vincent H., Kai‐Tai Chang, Mark LaRocco, et al.. (2007). Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease. 58(3). 309–314. 39 indexed citations
13.
Tam, Vincent H., et al.. (2006). Comparative Pharmacodynamics of Gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 50(8). 2626–2631. 98 indexed citations
14.
Tam, Vincent H., Amy N. Schilling, & Michael Nikolaou. (2005). Modelling time–kill studies to discern the pharmacodynamics of meropenem. Journal of Antimicrobial Chemotherapy. 55(5). 699–706. 102 indexed citations
15.
Tam, Vincent H., Amy N. Schilling, David Melnick, & Elizabeth A. Coyle. (2005). Comparison of β-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease. 52(2). 145–151. 21 indexed citations
16.
Tam, Vincent H., Amy N. Schilling, Shádi Neshat, et al.. (2005). Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 49(12). 4920–4927. 169 indexed citations
17.
Tam, Vincent H., et al.. (2005). Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 49(9). 3624–3630. 169 indexed citations
18.
Tam, Vincent H., Amy N. Schilling, Russell E. Lewis, David Melnick, & Adam Boucher. (2004). Novel Approach to Characterization of Combined Pharmacodynamic Effects of Antimicrobial Agents. Antimicrobial Agents and Chemotherapy. 48(11). 4315–4321. 28 indexed citations
19.
Ah, Owens, et al.. (1970). A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).. PubMed. 30(5). 1512–5. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Grégoire Breakdown of academic impact, for papers by Sofia K. Kasiakou Breakdown of academic impact, for papers by Michael A. Zhanel Breakdown of academic impact, for papers by Lisa Liolios Breakdown of academic impact, for papers by Neang S. Ly Breakdown of academic impact, for papers by Sachin Bhagwat Breakdown of academic impact, for papers by Roberto Andini Breakdown of academic impact, for papers by Courtney K. Lawrence Breakdown of academic impact, for papers by Kamilia Abdelraouf
Rankless by CCL
2026